Bionyra Pharma emerged from stealth after raising $165 million in an oversubscribed Series A to develop next-generation biologics for severe immunological and inflammatory diseases. The clinical-stage company was founded by Frédéric Marrache, who previously worked on immune-mediated drug development teams at Sanofi. The round was co-led by Jeito Capital and Sofinnova Partners, with participation from investors including Sanofi Ventures and Apollo Health Ventures. Board appointments include leadership from Jeito, Sofinnova, Arkin Bio, and Sanofi Ventures. The financing gives the new platform resources to advance pipeline programs in differentiated immune pathways, positioning Bionyra to compete in crowded but high-need inflammation biologics.